Seeking Alpha

The effectiveness of Novartis' (NVS) immune-system drug Certican was confirmed in the largest...

The effectiveness of Novartis' (NVS) immune-system drug Certican was confirmed in the largest trial to date of liver-transplant patients, with the treatment also able to improve renal function in the two-year Phase III study. Certican is approved in the EU for liver transplant patients, with an FDA approval decision expected at the end of the year. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector